The Expressions And Sence Of BRCA1 And U-PAR In The Epithelial Ovarian Tumor

Epithelial ovarian malignancy at the incidence of gynecological malignancies in third place,and mortality accounted is first. It is epithelial tumors account for 50% of primary ovarian tumor -70% of the malignant type of malignant ovarian tumors account for 85% of -90%. Early ovarian cancer-specific symptoms, the vast majority of patients when they seek medical treatment, his condition has entered a late stage. Although ovarian cancer treatment continue to improve, but with advanced ovarian cancer patients with 5-year survival rate is still hovering at around 20% -30%. The reason, mainly because of early ovarian cancer invasion and metastasis easily, resulting in the treatment of difficult and easy to relapse, poor prognosis. In recent years, more and more new development of ovarian cancer metastasis happened since the introduction of the monitoring role of the clinical indicators. Treatment for ovarian cancer provided a laboratory basis. Primarily through the article to explore in epithelial ovarian tumor in breast cancer susceptibility genes and urokinase-type plasminogen activator receptor protein and its clinical significance. Through concrete case the results of the analysis sample.BRCA1 are found to have genetic predisposition of breast cancer, ovarian cancer susceptibility gene .At cell proliferation and differentiation process, BRCA1, such as through DNA repair, cell cycle regulation, transcription factor regulation, centrosome replication process, as the role of negative regulator. Many experimental findings reported in BRCA1 mutation and familial breast and ovarian cancer has an important relationship, and on the dissemination of breast cancer and ovarian cancer or other malignant tumors the BRCA1 of the existence of the reports is relatively small. In the existing experimental results show that BRCA1 mutations and breast cancer clinical stage and differentiation must have the relationship with lymph node metastasis negative correlation. BRCA1 think this can become a breast cancer biomarker for thinning in patients with clinical stage, prognosis.This experiment will provide the finding of distributed ovarian cancer patients with BRCA1 mutations, the clinical stage and disease and the relationship between differentiation, analysis of its role in ovarian lesions, in order to BRCA1 research laboratory to provide a strong basisUrokinase-type plasminogen activator receptor is the lack of transmembrane and cytoplasmic part of the single-chain membrane glycoprotein receptor. Phthalocyanine through glycosyl phosphatidyl inositol (GP1)-anchored to the cell surface, is widely distributed in the human body. It not only fixed the limits of uPA, so that at the cell surface to form a P1 generated by the promotion of the environment, but also with a number of cell secretion of specific binding scu2PA through autocrine or paracrine mechanism scu2PA change with activity tcu2PA, and thus matrix degradation, regulating cell behavior(such as cell proliferation, migration and infiltration). Urokinase-type plasminogen activator slimming tumor receptor in the role, including regulation of cell surface protein cleavage activity, participation in signal transduction, regulating cell adhesion and migration, etc. This experiment will be at u-PaR expression of the ovarian lesions and a comparison with the disease, histological type and clinical stage of relations on the u-PaR in epithelial ovarian tumor of the role.Gene therapy has been the trend is gradually ripe. With an increasing number of tumor biomarkers, targeting a certain kind of gene therapy for malignant tumors of the Ways increasingly rich. If u-PaR, BRCA1 in sporadic ovarian epithelial tumors have occurred in the development of quantitative or qualitative change, then for ovarian cancer gene therapy provide an important basis for the laboratory. Such as the BRCA1 wild type of import, the use of antisense RNA technology to block the expression of u-PaR.even more scientific methodObjective:1 To explore the one of sporadic epithelial ovarian tumor in breast cancer susceptibility genes1 and disease change and clinical stage, the relationship between differentiation, with a view to understanding the role of breast cancer susceptibility gene in sporadic epithelial ovarian tumor occurrence and development2 Discussion of sporadic epithelial ovarian tumors in the expression of u-PaR and clinical stage of disease, the relationship between differentiation, know the role of u-PaR sporadic epithelial ovarian tumor occurrence and developmentMethods1to collect the second hospital in Hebei Province from January 2007 to August 2008 Gynecologic Oncology ward hospital surgical resection specimens, good wins 12 cases of ovarian tumor, borderline ovarian tumor 15 cases, 42 cases of ovarian cancer (69 patients without ovarian cancer and breast cancer family history) of all specimens are HE staining, confirmed by pathology, ovarian cancer patients with no pre-operative radiotherapy and chemotherapy. Ovarian cancer according to histological grade Lok Jie of the Ministry of Health Planning, editor-in-chief material, "Obstetrics and Gynecology," sixth edition textbook, (Senior poorly differentiated) G1 class one of 10 cases, G2 class 18 cases, G3 class Example 14; surgery one pathological class in 2000 according to FIGO standards, I view one of nine cases, II period of 11 cases, III period 12 cases, IV period 10 cases2 Immunohistochemical determination of the two methods in ovarian epithelial tumors. Urokinase-type plasminogen activator capacity fiber receptor positive staining of stomach biopsy as a urokinase-type plasminogen activator capacity fiber receptor positive control, known breast cancer susceptibility gene1 positive staining of human breast cancer tissue as a breast cancer susceptibility gene positive control 3 Analysis of the two separately in sporadic ovarian epithelial tumors of the change, to explore its role in epithelial ovarian tumor occurrence and developmentResults:1 urokinase-type plasminogen activator capacity fiber receptor protein in benign and malignant tumors of the positive expression rate between the difference was significant, there is statistical significance (P <0.05). In the borderline between the tumor and malignant tumors in benign and borderline tumor defibrase capacity between the urokinase-type plasminogen activator receptor protein positive expression rate There was no significant difference (P> 0.05), in epithelial of ovarian cancer in clinical stage between the expression of difference was significant, there is statistical significance (P <0.05), differentiation between the difference was significant, there is statistical significance (P <0.05), lymph node metastasis in the difference significant, there is statistical significance (P <0.05), urokinase-type plasminogen activator defibrase Yung receptor expression with age, histology type was no significant correlation ((P> 0.05)2Breast cancer susceptibility gene 1 protein in benign and malignant tumors between the positive expression rate of the difference has statistical significance (P <0.05), and at the junction between the tumor and malignant tumor in benign and borderline tumors between breast cancer susceptibility gene1 protein positive expression rate had no statistically significant differences (P> 0.05). In epithelial ovarian cancer in clinical stage between the expression of no significant difference (P> 0.05), differentiation between the difference was significant, there is statistical significance (P <0.05), lymph node metastasis in the difference was significant , there is statistical significance (P <0.05), breast cancer susceptibility gene expression with age and histological type had no correlation (P> 0.05)3 pairs of urokinase-type plasminogen activator capacity fiber receptor and breast cancer susceptibility gene1 expression analysis of rank correlation was found between the expression of the Spearman rank correlation coefficient was -0.350, P = 0.002 (P <0.05), with statistically significant difference, suggesting that ovarian cancer in urokinase-type plasminogen activator capacity fiber receptor and breast cancer susceptibility gene1 expression was a negative correlationConclusions1. Early, well-differentiated ovarian cancer defibrase urokinase-type plasminogen activator receptor capacity high expression, suggesting that urokinase-type plasminogen activator capacity fiber receptor at least in the early stage ovarian cancer occurrence and development play an important role2. Breast cancer susceptibility gene1 expression down to promote the occurrence of ovarian cancer development, is closely related to its invasion and metastasis3. Urokinase-type plasminogen activator capacity fiber receptor and breast cancer susceptibility gene1 expression was negatively correlated, suggesting that the two proteins probably through different channels, in the occurrence and development of ovarian cancer...